Tirzepatide (Mounjaro) has rapidly become one of the most discussed medications in diabetes and obesity medicine. Its dual GIP/GLP-1 receptor agonist mechanism produces unprecedented reductions in blood sugar and body weight. But what does the evidence say about its cardiovascular effects — and how does it compare to semaglutide? How Tirzepatide Works Unlike semaglutide, which…
English 
Urdu